ANOVO exits the US market and focuses on Europe
Texte intégral
(2) About A NOVO: With revenue of €317 million and 5,200 employees, A NOVO is the leading pan-European provider of maintenance and customisation services for the digital technologies used by major Telecommunications and Multimedia companies to deliver Triple Play (Voice/Data/Image) solutions. A NOVO runs more than 20 Centres of Excellence, and handles a high product turnover with an acknowledged level of quality. Compartment C of Eurolist by EuronextTM Paris - ISIN: FR0004152593 (shares), FR0000181174 (OCEANE convertible bonds), FR0000341174 (shares with warrants) Bloomberg: NOVO FP, Reuters: ANOV.LN. WorldReginfo - ec9ca069-b558-4533-af74-1c88e8cb6df2. ANOVO François Lefebvre, CFO Tel: +33 (0)1 58 17 00 81 flefebvre@a-novo.com.
(3)
Documents relatifs
Cervical cancer caused over 35,600 deaths in Latin America and the Caribbean in 2012, representing the second most com- mon cancer in women in this subregion.. Cost-effective
The majority of childhood cancer cases (65%) occur in Latin America and the Caribbean, where there is an estimated 17,500 children newly diagnosed and over 8,000 children dying
Several countries in Latin America and the Caribbean exhibit some of the highest rates for risk of dying from breast cancer, highlighting the inequities in health in the Region..
• The survival rate for colorectal cancer, measured indirectly through the incidence/mortality ratio, varies widely between North America and the rest of the region. • In
• The number of new prostate cancer cases and deaths will almost double by 2030 in Latin America and the Caribbean if current trends continue.. Proportion of new cases
Lung cancer incidence and mortality age-standardized rates (per 100,000) and prevalence of current adult smokers* (%) among women, 2012.. • An estimated 84% of lung cancer deaths
• If current trends continue, cervical cancer is projected to increase in Latin America and the Caribbean by 45% in the number of new cases and by 60% in number of deaths, by
A total of 35 countries from the Americas provided written responses to the questionnaire, which included information on their cancer policy and plans, cancer registration,